Cancer Center Support Grant

描述（由申请人提供）：对癌症的遗传学理解增强了个体风险评估，改进了筛查指南，并改善了基于癌症预防、早期检测和某些情况下靶向治疗的结果。亨斯迈癌症研究所（HCI）的定位是在这一个体化肿瘤竞技场做出卓越贡献。HCI拥有独特的研究资源，以支持遗传和人口研究，犹他州人口数据库（CQB），肿瘤学遗传发现的引人注目的历史，以及加速该平台转化进展的战略计划。我们已经与Intermountain Healthcare结成联盟，这是一个全国知名的犹他州健康网络，将我们州80- 85%以上的癌症患者的数据连接到CQB，使犹他州的整个人口能够组成一个癌症研究实验室，进行遗传，人口和结果研究。犹他州是七个美洲原住民部落或民族以及广泛的农村和边境人口的家园，这些人口的癌症预后很差。我们的目标是作为一个国家的研究资源，以满足这些服务不足的人群，以改善癌症预防和护理的需求。 HCI研究分为五个项目，提供癌症焦点，跨学科交流和合作的环境：细胞生长和分化的核控制;细胞反应和调节;成像，诊断和治疗;胃肠道癌症;癌症控制和人口科学。这些方案整合了133名成员的活动，这些成员拥有4 500万美元的校外赠款支持，NCI直接费用超过1 700万美元。在目前的奖项期间，以癌症为重点的研究记录在1，374种独特的出版物中，其中26%是与一个或多个癌症中心成员合作。十三癌症中心共享资源支持我们的科学家，提供专业仪器，分析，服务，研究材料，专家咨询和合作。 我们要求资金支持我们的癌症中心支持补助金（CCSG）的21-25年。新的执行董事，玛丽贝克尔，博士，于2006年8月被任命。在她的领导下，HCI制定了一项指导未来五年的计划，包括扩大HCI的癌症专科医院，扩大HCI的临床前研究遗传平台，开发研究性治疗中心（包括I期计划），以及扩大人口科学（包括流行病学和行为研究），以影响癌症幸存者的护理，减少健康差距。

DESCRIPTION (provided by applicant): The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute (HCI) is positioned to make exceptional contributions in this individualized oncology arena. HCI has a unique research resource to support genetic and population studies, the Utah Population Database (UPDB), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. We have forged an alliance with Intermountain Healthcare, a nationally acclaimed Utah health network, linking data for more than 80-85 percent of the cancer patients in our State to the UPDB, enabling the entire population of Utah to comprise a cancer research laboratory for genetic, population, and outcomes research. Utah is home to seven Native American tribes or nations as well as extensive rural and frontier populations that have poor cancer outcomes. We aim to serve as a national research resource for addressing the needs of these underserved populations to improve cancer prevention and care. HCI research is organized into five Programs that provide an environment of cancer focus, transdisciplinary exchange, and collaboration: Nuclear Control of Cell Growth and Differentiation; Cell Response and Regulation; Imaging, Diagnostics, and Therapeutics; Gastrointestinal Cancers; and Cancer Control and Population Sciences. These Programs integrate the activities of 133 members who have $45 million in extramural grant support, with more than $17 million in NCI direct costs. Cancer-focused research during the current award period is documented in 1,374 unique publications, of which 26 percent are collaborative with one or more Cancer Center members. Thirteen Cancer Center Shared Resources support our scientists, providing access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. We request funds to support Years 21-25 of our Cancer Center Support Grant (CCSG). A new Executive Director, Mary Beckerle, Ph.D., was appointed in August 2006. Under her leadership, HCI has developed a plan to guide the next five years, including expansion of HCI's cancer specialty hospital, expansion of HCI's genetic platform for pre-clinical studies, development of a Center for Investigational Therapeutics (including a Phase I program), and expansion of population science (including epidemiological and behavioral research) to impact care of cancer survivors and reduce health disparities.